Last Updated on October 8, 2021 by The Health Master
The National Pharmaceutical Pricing Authority (NPPA) has released the draft ceiling price of two formulations, mentioned below, which are compositions under the National List of Essential Medicine (NLEM).
- Methylthioninium chloride also known as methylene blue
- Hydroxocobalamin injection
The final ceiling price of methylene blue 10 mg/ml injection, used or the treatment of methemoglobinemia and cancer, has been fixed at Rs. 21.85 per ml without Goods and Services Tax (GST), which is 10.30 per cent lower than the highest price in the market.
There are three players with market share of one per cent or above and the total moving annual total (MAT) for the drug is around Rs 1.34 crore.
The companies which have one per cent or more share in the market include Vulcan Laboratories, Samarth Life Sciences Pvt Ltd and Flagship Biotech International.
Flagship’s brand Blue Beam is sold at Rs 20.88 per ml in the market, while Vulcan Labs has the lowest price for its brand Bluject, at Rs 16.70 per unit.
The final ceiling price of hydroxocobalamin injection 1mg/ml, a dietary supplement used to treat deficiency of vitamin B12, has been fixed at Rs 9.91per ml.
The formulation currently has only one player with one per cent or above market share, which is Tridoss Laboratories Pvt Ltd which sells the brand Trineurosol HP injection in two strengths.
The company sells the drug at Rs 10.93 per unit. The total MAT of the drug is Rs 3.44 crore, said the NPPA calculation sheet.
The NPPA,, earlier this week, has released a draft version of a proposed retail price calculation sheet for seven formulations including from Mankind Pharma Ltd, Panacea Biotech, Troikaa Pharmaceuticals and others.